Pharma firms ask for December 2026 as extension for implementation of rules

  • Industry News
  • Aug 28,24
Schedule M of the Drugs and Cosmetics Rules, 1945, outlines good manufacturing practices (GMP) for pharmaceutical products, including a prompt recall system for defective products.
Pharma firms ask for December 2026 as extension for implementation of rules

India's pharmaceutical industry is requesting an additional two years to implement the revised manufacturing rules under Schedule M, arguing that the extension is crucial for the survival of micro, small, and medium enterprises (MSMEs). Schedule M of the Drugs and Cosmetics Rules, 1945, outlines good manufacturing practices (GMP) for pharmaceutical products, including a prompt recall system for defective products.

 

Pharmaceutical lobby groups have approached the health minister, seeking to extend the current December 2024 deadline to December 2026, citing resource constraints and industry challenges in meeting the revised standards.

 

The health ministry notified the updated Schedule M rules in January 2024. Laghu Udyog Bharati (LUB), an affiliate of RSS, and the Federation of Pharma Entrepreneurs (FOPE), representing MSME pharma units, have formally requested Health Minister J.P. Nadda to delay the implementation. "Implementing the rules by December 2024 would be too soon for MSME pharma units," Laghu Udyog Bharati stated in its letter, emphasising that more time is needed, especially with ongoing production, as a one-year period is insufficient for such an upgrade.

(ET)

Related Stories

Process Equipment
50 new plants to be established under pharma and medical device PLI scheme

50 new plants to be established under pharma and medical device PLI scheme

In the first five months of this fiscal year, the pharma and meditech sectors have become the fourth largest manufacturing export sector in India, following automotive, petrochemicals, and electroni..

Read more
Policy Regulation
Bright future for manufacturing as ‘Make in India’ marks 10 years: Piyush Goyal

Bright future for manufacturing as ‘Make in India’ marks 10 years: Piyush Goyal

Other sectors like steel, cement, and textiles have seen massive investments, contributing to the overall growth of India’s manufacturing capacity.

Read more
Process Equipment
Aurobindo to acquire remaining 49% stake in GLS Pharma for Rs 225 million

Aurobindo to acquire remaining 49% stake in GLS Pharma for Rs 225 million

Aurobindo initially acquired a 51% stake in GLS Pharma from promoters Suresh Pathak and his family on June 17, 2022.

Read more

Related Products

Programmable Controllers - Pcd-33a Series

CHEMICAL PROCESS, FOOD/PHARMA EQUIPMENT & ANALYTICAL INSTRUMENTS

Pro-Med Instruments (P) Ltd offers a wide range of programmable controllers - PCD-33A Series.


Read more

Request a Quote

Gasket Graphite Powder

CHEMICAL PROCESS, FOOD/PHARMA EQUIPMENT & ANALYTICAL INSTRUMENTS

Arihant Packing & Gasket Company offers a wide range of gasket graphite powder. 


Read more

Request a Quote

Asahi Kasei expands 3D printing filament sales in North America

CHEMICAL PROCESS, FOOD/PHARMA EQUIPMENT & ANALYTICAL INSTRUMENTS

Asahi Kasei, a leading resin and compounding technology provider, has initiated the sales of 3D printing (3DP) filaments in North America through Asahi Kasei Plastics North America (APNA). The soft la Read more

Request a Quote

Hi There!

Now get regular updates from IPF Magazine on WhatsApp!

Click on link below, message us with a simple hi, and SAVE our number

You will have subscribed to our Industrial News on Whatsapp! Enjoy

+91 84228 74016

Reach out to us

Call us at +91 8108603000 or

Schedule a Call Back